Ballew Advisors’s Ocular Therapeutix OCUL Stock Holding History

Ballew Advisors’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-200	Closed	-$1K	–	341
2018 Q3	$1K	Buy	+200	New	+$1.25K	﹤0.01%	448

Other funds holding OCUL

Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DAM

Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return

SHI

SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return

Ballew Advisors's OCUL Position: Q4 2018 in Review

Ballew Advisors sold out of Ocular Therapeutix (OCUL) in Q4 2018, closing a stake of 200 shares — an estimated $1K sold.

Ballew Advisors first reported a position in OCUL in Q3 2018 and held it in 1 quarter. The position peaked at $1K in Q3 2018. 69 funds tracked by Wall St. Rank hold OCUL as of Q4 2018.

Ballew Advisors reported no remaining Ocular Therapeutix position as of Q4 2018 after selling out during the quarter.
Ballew Advisors sold 200 Ocular Therapeutix shares in Q4 2018, an estimated $1K.
Ballew Advisors first reported a position in Ocular Therapeutix in Q3 2018 and held it in 1 quarter.
Ballew Advisors's Ocular Therapeutix position peaked at $1K in Q3 2018.
69 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q4 2018.

Based on Ballew Advisors's 13F filing for Q4 2018, filed 12 Feb 2019.